Skip to main content

Oncology Care

Seattle Children's Lands on U.S. News Top 10 List for Third Year Straight

Seattle – September 17, 2026 -- Seattle Children's has secured a spot on U.S. News & World Report's Best Children's Hospitals Honor Roll for the third consecutive year, a recognition given to only 10 hospitals nationwide.

The hospital ranked No. 1 in Washington state and tied for No. 1 in the Pacific region, which covers Alaska, California, Hawaii, Oregon and Washington.

Four specialties crack the national top 10

Seattle Children's ranked in every specialty category evaluated by U.S. News. Four of those specialties -- Cancer, Diabetes & Endocrinology, Nephrology, and Pulmonology & Lung Surgery -- placed among the top 10 in the country.

Cobblestone Car Wash Donates $1 Per Wash to Fight Pediatric Cancer

Boise, Idaho – September 15, 2026 -- Cobblestone Car Wash is donating $1 from every GrapheneX Express Exterior wash purchased at any of its Idaho locations throughout September to St. Luke's Children's Hospital's pediatric cancer research program.

The initiative coincides with Childhood Cancer Awareness Month and applies to all 14 Cobblestone locations across Idaho.

Roughly 15,000 children are diagnosed with cancer annually in the US

Cobblestone and St. Luke's Children's Hospital cite this figure as the basis for the campaign, which aims to fund improved treatment options, new therapy development, survivorship care, and reduced disparities in pediatric cancer outcomes.

Customers simply upgrade their wash to trigger the donation

Any driver who selects the GrapheneX Express Exterior wash at a participating Idaho location during September automatically generates the $1 donation, with no additional steps required.

Lung Association Pushes Clinical Trial Awareness to Close Cancer Care Gaps

Chicago – September 13, 2026 -- The American Lung Association is expanding its Awareness, Trust and Action campaign to encourage more lung cancer patients to ask their doctors about clinical trials as a treatment option.

Every current lung cancer treatment originated in a clinical trial

"Clinical trials provide the most promising way to improve treatment outcomes and continue advancements in lung cancer care and survivorship," said Harold Wimmer, President and CEO of the American Lung Association. He said the organization wants patients and caregivers to discuss all treatment options, including trials, with their healthcare providers.

Free Kidney Patient Summit Hits Little Rock With Free Meals, Meds Talk

Little Rock – September 12, 2026 -- The American Association of Kidney Patients (AAKP) will host its 51st annual National Patient Meeting September 10-13, 2026, in Little Rock, Arkansas, with free admission and meals for kidney patients, family members, care partners, and living organ donors. Pre-registration is encouraged online or by calling (800) 749-2257.

The event opens with a free policy forum at the Clinton Presidential Center

AAKP's Public Policy Forum runs September 10 from 1:00 p.m. to 4:00 p.m. CT at the William J. Clinton Presidential Center, with doors opening at noon and lunch provided. The session covers kidney research, innovation, and how federal regulatory and reimbursement decisions affect patient care. Registration is required.

Kevin Costner Fronts Campaign for New Blood Test That Detects Cancer Early

Irving, Texas – September 11, 2026 -- Caris Life Sciences has launched a national awareness campaign called "Math," featuring actor Kevin Costner, to promote Caris Detect, a multi-cancer early detection blood test now available across the United States.

The blood test screens for cancer signals before symptoms appear

Caris Detect combines ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing, and artificial intelligence to scan the bloodstream for molecular signals associated with cancer. Unlike tests that check only a limited set of biomarkers, the company says its approach analyzes the entire genome and transcriptome for a broader molecular picture. The test is designed to complement, not replace, routine cancer screenings.

New Docuseries Exposes Deadly Myths of 'Germanic New Medicine'

Munich – September 09, 2026 -- A new two-part investigative docuseries, "Seelenfänger: Der falsche Heiler," premieres October 13, 2026 in the ARD Mediathek and airs October 19, 2026 at 11:30 p.m. on BR Fernsehen, documenting families who lost loved ones after they trusted the pseudo-medical theory known as "Germanische Neue Medizin" (Germanic New Medicine).

The theory rejects evidence-based cancer treatment

Germanic New Medicine frames cancer not as a disease but as the physical manifestation of an unresolved psychological conflict. Followers of the theory are encouraged to reject conventional, evidence-based medical treatment -- a choice the docuseries links directly to preventable deaths.

Doctor's Own Cancer Scare Shows 'Normal' PSA Can Still Hide Danger

Somerset, N.J. – September 08, 2026 -- A prostate cancer specialist with more than 30 years of experience says his own diagnosis nearly slipped through the cracks despite a PSA reading that looked normal, a warning he's sharing as ProCure Proton Therapy Center marks National Prostate Cancer Awareness Month.

Dr. Edward Soffen said his PSA level was actually slightly lower than it had been six months earlier when his urologist flagged the result as 'labile,' meaning it fluctuates. That prompted a urine DNA test, which showed a 50 percent malignancy risk. A follow-up MRI and biopsy confirmed cancer.

A PSA under 4 ng/mL doesn't rule out cancer

Dr. Soffen said men with PSA readings in the 'normal' range, under 4 ng/mL, should still report any fluctuation to their doctor and ask about additional testing that can catch cancers PSA alone might miss.

Spine Institute Lists Questions Patients Should Ask Before Back Surgery

Hudson, Florida – September 07, 2026 -- The Bonati Spine Institute has published a list of questions it says chronic back and neck pain patients should ask any surgeon proposing spinal surgery, timed to September's Pain Awareness Month.

"Most of the people who come to us have been in pain for years, and most of them have been treated for years," said Dr. Alfred Bonati, founder and chief orthopedic surgeon of the institute. "Many of them have never gotten a straight answer to one basic question: what specifically is generating this pain, and how do you know?"

30% of Men Over 55 Skip Prostate Cancer Screening, Survey Finds

Columbia, Md. – September 07, 2026 -- A new national survey from MedStar Health finds that 30% of men age 55 and older have never had a prostate exam, and nearly four in ten have skipped the prostate-specific antigen (PSA) blood test, despite prostate cancer being one of the most common cancers in men.

PSA screening is recommended at least every two to four years for average-risk men ages 55 through 69. About one in eight men will be diagnosed with prostate cancer during their lifetime.

Doctors say vague early symptoms lead men to delay testing

"Prostate cancer is common, and it may not cause clear symptoms early on," said Jonathan J. Hwang, MD, chair of Urology at MedStar Washington Hospital Center. "These findings show that many men may be putting off screening or may not know what warning signs to watch for."

75 Years of Cancer Research Have Given Patients 26 Million Extra Years of Life

Washington – September 07, 2026 -- A new analysis published in Blood Advances finds that treatment advances for leukemia, lymphoma, myeloma and other blood cancers have saved an estimated 25.8 million life-years in the United States since 1949. The study, led by Blood Cancer United, introduces a first-of-its-kind "life-years saved" methodology built on data from the National Cancer Institute's SEER Program, tracking cancer incidence, mortality and U.S. life expectancy from the era of the first chemotherapies through 2024.

Blood cancers now account for nearly 10% of all U.S. cancer diagnoses, with more than 192,000 new cases expected this year. Unlike many solid tumors, where screening and prevention drive survival gains, progress against blood cancers depends almost entirely on new therapies and access to them.